Placing the highest value on human capital.

From our inception in 2008, every hiring decision, strategic partnership, and engagement with external policy makers, clients, and investors has been driven by a commitment to the highest ethical standards, deep mutual respect, and a spirit of collaboration.

Recombinetics has strategically built our organization around three core markets—biomedical research, regenerative medicine, and a safe, abundant food supply. Our business platforms continue to progress supported by an expert internal science team, proven executive team, and an array of noted advisors, partners and specialized staff.

our leadership

Mark Platt

Mark Platt

Chief Executive Officer
David Aberle

David Aberle, M.B.A.

Chief Financial Officer & VP of Finance
Dan Carlson

Dan Carlson, Ph.D.

Chief Scientific Officer and SVP of Research & Development

Tad Sonstegard, Ph.D.

Chief Executive & Scientific Officer  |  Acceligen
John Burtis

John Burtis, J.D.

Vice President of Legal
Adrienne Watson

Adrienne Watson, Ph.D.

Vice President of Research & Development

our board

Jerry Arndt

Jerry Arndt

Bill Farrell

Bill Farrell

Peter Hajas

Peter Hajas

Perry Hackett

Perry Hackett

David Laraespada

David Largaespada

Scott Rathgaber

Scott Rathgaber, M.D.

Justin Zananko

Justin Zenanko

Your investment can help us change the world.

Reach out today for information on how you can make a difference.